M-110 | CAS#1395048-49-3 | PRMT inhibitor

M-110
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 558399

CAS#: 1395048-49-3

Description: M-110 is a inhibitor of protein arginine N-methyltransferases (PRMTs). It is also a highly isoform-selective, cell permeable and potent ATP-competitive inhibitor of the PIM kinase family that prefers PIM-3, shown to inhibit the proliferation of prostate cancer cell lines with IC50s between 0.6 to 0.9 μM, with no activity on normal human peripheral blood mononuclear cells up to 40 μM.

Chemical Structure

M-110

CAS# 1395048-49-3

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 558399
Name: M-110
CAS#: 1395048-49-3
Chemical Formula: C22H28ClN5O3
Exact Mass: 445.19
Molecular Weight: 445.948
Elemental Analysis: C, 59.25; H, 6.33; Cl, 7.95; N, 15.70; O, 10.76

Price and Availability

Size	Price	Availability
5mg	USD 350	2 weeks
25mg	USD 850	2 weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: M-110; M 110; M110;

IUPAC/Chemical Name: (E)-2-(3-Morpholin-4-yl-propylamino)-isonicotinic acid [1-(4-chloro-2-hydroxy-phenyl)-propylidene]-hydrazide

InChi Key: FXXCNYVQIONABS-LGUFXXKBSA-N

InChi Code: InChI=1S/C22H28ClN5O3/c1-2-19(18-5-4-17(23)15-20(18)29)26-27-22(30)16-6-8-25-21(14-16)24-7-3-9-28-10-12-31-13-11-28/h4-6,8,14-15,29H,2-3,7,9-13H2,1H3,(H,24,25)(H,27,30)/b26-19+

SMILES Code: O=C(N/N=C(C1=CC=C(Cl)C=C1O)\CC)C2=CC=NC(NCCCN3CCOCC3)=C2

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	M-110 is a highly selective, ATP-competitive inhibitor of PIM kinases with a preference for PIM-3 (IC50=47 nM).
In vitro activity:	Introduction of structural modifications yielded compound M-110, which inhibits the proliferation of prostate cancer cell lines with IC(50)s of 0.6 to 0.9 μmol/L, with no activity on normal human peripheral blood mononuclear cells up to 40 μmol/L. Screening of 261 recombinant kinases and subsequent analysis revealed that M-110 is a selective inhibitor of the PIM kinase family, with preference for PIM-3. Treatment of DU-145 cells with M-110 or with a structurally unrelated PIM inhibitor, SGI-1776, significantly reduces pSTAT3(Tyr705) expression without affecting the expression of STAT3. Furthermore, treatment of DU-145 cells with M-110 attenuates the interleukin-6-induced increase in pSTAT3(Tyr705). Reference: Mol Cancer Ther. 2010 Sep;9(9):2478-87. https://pubmed.ncbi.nlm.nih.gov/20667852/
In vivo activity:	TBD

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMSO	33.3	74.74

Preparing Stock Solutions

The following data is based on the product molecular weight 445.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	Chang M, Kanwar N, Feng E, Siu A, Liu X, Ma D, Jongstra J. PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation. Mol Cancer Ther. 2010 Sep;9(9):2478-87. doi: 10.1158/1535-7163.MCT-10-0321. Epub 2010 Jul 28. PMID: 20667852.
In vitro protocol:	Chang M, Kanwar N, Feng E, Siu A, Liu X, Ma D, Jongstra J. PIM kinase inhibitors downregulate STAT3(Tyr705) phosphorylation. Mol Cancer Ther. 2010 Sep;9(9):2478-87. doi: 10.1158/1535-7163.MCT-10-0321. Epub 2010 Jul 28. PMID: 20667852.
In vivo protocol:	TBD

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Gailly P, Wu X, Haystead TA, Somlyo AP, Cohen PT, Cohen P, Somlyo AV. Regions of the 110-kDa regulatory subunit M110 required for regulation of myosin-light-chain-phosphatase activity in smooth muscle. Eur J Biochem. 1996 Jul 15;239(2):326-32. PubMed PMID: 8706736.

2: Johnson D, Cohen P, Chen MX, Chen YH, Cohen PT. Identification of the regions on the M110 subunit of protein phosphatase 1M that interact with the M21 subunit and with myosin. Eur J Biochem. 1997 Mar 15;244(3):931-9. PubMed PMID: 9108268.

3: Johnson DF, Moorhead G, Caudwell FB, Cohen P, Chen YH, Chen MX, Cohen PT. Identification of protein-phosphatase-1-binding domains on the glycogen and myofibrillar targetting subunits. Eur J Biochem. 1996 Jul 15;239(2):317-25. PubMed PMID: 8706735.

4: Calhoun MW, Lemieux LJ, Garcia-Horsman JA, Thomas JW, Alben JO, Gennis RB. The highly conserved methionine of subunit I of the heme-copper oxidases is not at the heme-copper dinuclear center: mutagenesis of M110 in subunit I of cytochrome bo3-type ubiquinol oxidase from Escherichia coli. FEBS Lett. 1995 Jul 24;368(3):523-5. PubMed PMID: 7635213.

5: Dvir H, Choe S. Bacterial expression of a eukaryotic membrane protein in fusion to various Mistic orthologs. Protein Expr Purif. 2009 Nov;68(1):28-33. doi: 10.1016/j.pep.2009.06.007. Epub 2009 Jun 12. PubMed PMID: 19524676; PubMed Central PMCID: PMC2728152.

6: Seddiki T, Delpal S, Aubourg A, Ollivier-Bousquet M. Two monoclonal antibodies against prolactin-receptor are internalized in epithelial mammary cells without mimetic prolactin effect on casein secretion. Biol Cell. 1994;81(3):227-35. PubMed PMID: 7696976.

7: Djiane J, Dusanter-Fourt I, Katoh M, Kelly PA. Biological activities of binding site specific monoclonal antibodies to prolactin receptors of rabbit mammary gland. J Biol Chem. 1985 Sep 25;260(21):11430-5. PubMed PMID: 2995334.

8: Lee BY, Ahn MH, Kim HC, Min DY. Toxoplasma gondii: ultrastructural localization of specific antigens and inhibition of intracellular multiplication by monoclonal antibodies. Korean J Parasitol. 2001 Mar;39(1):67-75. PubMed PMID: 11301592; PubMed Central PMCID: PMC2721067.

9: Katoh M, Djiane J, Kelly PA. Monoclonal antibodies against rabbit mammary prolactin receptors. Specific antibodies to the hormone binding domain. J Biol Chem. 1985 Sep 25;260(21):11422-9. PubMed PMID: 2995333.

10: Guo LT, Helgadóttir S, Söll D, Ling J. Rational design and directed evolution of a bacterial-type glutaminyl-tRNA synthetase precursor. Nucleic Acids Res. 2012 Sep;40(16):7967-74. doi: 10.1093/nar/gks507. Epub 2012 May 31. PubMed PMID: 22661575; PubMed Central PMCID: PMC3439900.

11: Sands NB, Adamson PA. Nasal tip deprojection with crural cartilage overlap: the M-arch model. Facial Plast Surg Clin North Am. 2015 Feb;23(1):93-104. doi: 10.1016/j.fsc.2014.09.007. Review. PubMed PMID: 25430931.

12: Dvir H, Lundberg ME, Maji SK, Riek R, Choe S. Mistic: cellular localization, solution behavior, polymerization, and fibril formation. Protein Sci. 2009 Jul;18(7):1564-70. doi: 10.1002/pro.148. PubMed PMID: 19475664; PubMed Central PMCID: PMC2775223.

13: Jenny C. A possible mechanism for accidental humeral fractures in infants. Pediatr Radiol. 2014 Oct;44(10):1218. doi: 10.1007/s00247-014-3098-6. Epub 2014 Aug 2. PubMed PMID: 25085440.

14: Sands NB, Adamson PA. Pediatric esthetic otoplasty. Facial Plast Surg Clin North Am. 2014 Nov;22(4):611-21. doi: 10.1016/j.fsc.2014.07.008. Epub 2014 Nov 8. Review. PubMed PMID: 25444732.

15: Chen YH, Chen MX, Alessi DR, Campbell DG, Shanahan C, Cohen P, Cohen PT. Molecular cloning of cDNA encoding the 110 kDa and 21 kDa regulatory subunits of smooth muscle protein phosphatase 1M. FEBS Lett. 1994 Dec 12;356(1):51-5. PubMed PMID: 7988720.

16: Yuan H, Amin R, Ye X, de la Motte CA, Cowman MK. Determination of hyaluronan molecular mass distribution in human breast milk. Anal Biochem. 2015 Apr 1;474:78-88. doi: 10.1016/j.ab.2014.12.020. Epub 2015 Jan 9. PubMed PMID: 25579786; PubMed Central PMCID: PMC4357551.

17: MacDonald JA, Eto M, Borman MA, Brautigan DL, Haystead TA. Dual Ser and Thr phosphorylation of CPI-17, an inhibitor of myosin phosphatase, by MYPT-associated kinase. FEBS Lett. 2001 Mar 30;493(2-3):91-4. PubMed PMID: 11287002.

18: Dong J, Ren L, Zhang Y, Cui X, Hu P, Xu J. Direct electrodeposition of cable-like CuO@Cu nanowires array for non-enzymatic sensing. Talanta. 2015 Jan;132:719-26. doi: 10.1016/j.talanta.2014.10.027. Epub 2014 Oct 22. PubMed PMID: 25476370.

19: Assah F, Mbanya JC, Ekelund U, Wareham N, Brage S. Patterns and correlates of objectively measured free-living physical activity in adults in rural and urban Cameroon. J Epidemiol Community Health. 2015 Jul;69(7):700-7. doi: 10.1136/jech-2014-205154. Epub 2015 Apr 3. PubMed PMID: 25841243; PubMed Central PMCID: PMC4484252.

20: Adamson PA, Constantinides M, Kim AJ, Pearlman S. Rhinoplasty: panel discussion. Facial Plast Surg Clin North Am. 2014 Feb;22(1):25-55. doi: 10.1016/j.fsc.2013.09.001. Review. PubMed PMID: 24290994.

Your view history

M-110 featured